Showing results (241-250 of 254) with videos related to
Sort By:
Pageof 26
Gut|July 30, 2017
The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosisDai-Min Xiang, Wen Sun, Bei-Fang Ning, et al.Ebiomedicine|December 28, 2021
Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trialLei Shi, Xin Yuan, Weiqi Yao, et al.Frontiers in Medicine|June 1, 2022
15-Month Health Outcomes and the Related Risk Factors of Hospitalized COVID-19 Patients From Onset: A Cohort StudyLiang-Liang Sun, Jian Wang, Yu-Sheng Wang, et al.Hepatology International|January 1, 2021
Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosisXin Zeng, Xia Sheng, Pei-Qin Wang, et al.Journal of Advanced Research|May 27, 2025
Fibrinogen exacerbates α-synuclein aggregation and mitochondrial dysfunction via alpha5beta3 integrin in Parkinson's diseaseZifeng Huang, Jialing Zheng, Feilan Yuan, et al.Signal Transduction and Targeted Therapy|July 28, 2025
Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insightsLei Shi, Ziying Zhang, Song Mei, et al.Stem Cell Research & Therapy|February 26, 2025
Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trialMeng-Qi Yuan, Le Song, Ze-Rui Wang, et al.Journal of Agricultural and Food Chemistry|July 4, 2020
Feature-Based Molecular Networking Analysis of the Metabolites Produced by In Vitro Solid-State Fermentation Reveals Pathways for the Bioconversion of Epigallocatechin GallateHao-Fen Xie, Ya-Shuai Kong, Ru-Ze Li, et al.Journal of Digestive Diseases|April 9, 2023
Prevalence and risk factors of covert hepatic encephalopathy in cirrhotic patients: A multicenter study in ChinaXin Zeng, Chuan Yin, Chun Yan Sun, et al.Ebiomedicine|May 7, 2023
Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trialTian-Tian Li, Bo Zhang, Hui Fang, et al.Pageof 26